Derrick Sung - 01 Dec 2025 Form 4 Insider Report for Pulmonx Corp (LUNG)

Reporting relationship: COO and CFO
Issuer ticker: LUNG
Reported as of: 01 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Dec 2025, 19:45:52 UTC
Prior SEC filing: 10 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ David Aaron Lehman, Attorney-in-Fact

Key filing fact

Derrick Sung filed Form 4 for Pulmonx Corp (LUNG) on 03 Dec 2025.

Key facts

This page summarizes Derrick Sung's Form 4 filing for Pulmonx Corp (LUNG).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Dec 2025, 19:45.

Change

Previous filing in this sequence was filed on 10 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001670118 Primary reporting owner

Sung Derrick

Relationship: COO and CFO
Address: C/O PULMONX CORPORATION, 700 CHESAPEAKE DRIVE, REDWOOD CITY
Signature: /s/ David Aaron Lehman, Attorney-in-Fact
Signature date: 02 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LUNG transaction

Common Stock

Award

Transaction value: $0
Shares: +1,200,000
Change %: +887%
Price: $0.000000
Shares after: 1,335,319
Date: 01 Dec 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LUNG transaction Derivative

Performance Stock Units

Award

Transaction value: $0
Shares: +400,000
Change %
Price: $0.000000
Shares after: 400,000
Date: 01 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400,000
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents grant of Restricted Stock Units payable solely in common stock of the Issuer, 25% of which vests one year from the grant date of December 1, 2025, and the remainder vests in equal quarterly installments over the three-year period following the date of grant.

Footnote F2

Each Performance Stock Unit represents a contingent right to receive one share of the Issuer's common stock. The Performance Stock Units vest upon meeting the following two conditions: (a) upon the Issuer's common stock achieving a specified price per share and (b) with respect to 33% on the one year following the grant date of December 1, 2025 and the remainder in eight equal quarterly installments.